XM does not provide services to residents of the United States of America.
G
G

Grifols

Trade Ideas

Traders Sentiment

Technical Summary

Hourly

News

Brookfield has room to sweeten Spanish drug deal

BREAKINGVIEWS-Brookfield has room to sweeten Spanish drug deal The author is a Reuters Breakingviews columnist. The opinions expressed are her own. By Yawen Chen LONDON, Nov 20 (Reuters Breakingviews) - One of Europe’s largest buyouts this year may need a shot in the arm. Beleaguered Spanish pharma company Grifols GRLS.MC has rejected a 6.45 billion euro non-binding offer from Canadian private equity house Brookfield BN.TO , claiming it significantly undervalued the firm.
G
S

Spanish stocks - Factors to watch on Nov 20

Spanish stocks - Factors to watch on Nov 20 Nov 20 (Reuters) - The following Spanish stocks may be affected by newspaper reports and other factors on Wednesday. Reuters has not verified the newspaper reports, and cannot vouch for their accuracy: INDITEX ITX.MC Zara owner Inditex has sharply increased its use of air freight to bring clothes from factories in India to its logistics hub in Spain to avoid shipping delays, according to trade data, industry experts, and investors.
G
I
S

Grifols Says It Would Not Recommend Shareholders Accept Brookfield's Bid Offer

BRIEF-Grifols Says It Would Not Recommend Shareholders Accept Brookfield's Bid Offer Nov 20 (Reuters) - Grifols GRLS.MC : SAID ON TUESDAY POTENTIAL OFFER BY BROOKFIELD FOR ENTIRE OUTSTANDING SHARE CAPITAL OF CO, IMPLYING INDICATIVE PRICE OF EUR 10.50 PER SHARE FOR CLASS A SHARES, SIGNIFICANTLY UNDERVALUES CO'S FUNDAMENTAL PROSPECTS AND LONG-TERM PO
G

Grifols: Brookfield's potential $6.8 bln offer undervalues the firm

UPDATE 2-Grifols: Brookfield's potential $6.8 bln offer undervalues the firm Adds board not recommending to sell, updates share price MADRID, Nov 19 (Reuters) - Grifols GRLS.MC said on Tuesday that Canadian investment fund Brookfield's potential 6.45 billion euro ($6.8 billion) offer significantly undervalued the Spanish drugmaker's prospects and long-term potential, telling shareholders to stick to their shares .
G
S

Spanish court opens investigation into Gotham City's attack on Grifols

UPDATE 1-Spanish court opens investigation into Gotham City's attack on Grifols Adds details, comment from the court and context MADRID, Nov 19 (Reuters) - An investigating magistrate at Spain's High Court has opened a probe into U.S.-based short seller Gotham City Research's actions that hammered the share price of Spanish pharmaceutical firm Grifols GRLS.MC in January .
G

Conditions

Popular Assets

Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.

All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.

Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.

Risk Warning: Your capital is at risk. Leveraged products may not be suitable for everyone. Please consider our Risk Disclosure.